Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 01:27pm CEST
   By Melodie Warner 
 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at [email protected]

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
06/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Pataday® ..
06/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Zetia® in the Unite..
06/22 TEVA PHARMACEUTICAL INDUSTRIES : loses $235m patent trial to GSK
06/19 TEVA PHARMACEUTICAL INDUSTRIES : AbCellera expands research collaboration with T..
06/16 TEVA PHARMACEUTICAL INDUSTRIES : embroiled in Copaxone dosage levels dispute
06/15 TEVA PHARMACEUTICAL INDUSTRIES : Fremanezumab Meets all Primary & Secondary Endp..
06/15 CTI BIOPHARMA : Hikes on Teva Milestone Payment
06/14 TEVA PHARMACEUTICAL INDUSTRIES : launches generic cholesterol treatment
06/14 TEVA PHARMACEUTICAL INDUSTRIES : launches generic allergic eye treatment Pataday..
06/13 TEVA PHARMACEUTICAL INDUSTRIES : launches generic cholesterol treatment
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 JUNE BUYS : The 16 Stocks Added To My Fund
06/22 Drug stocks rally on GOP draft of healthcare bill
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 FDA aims at removing barriers to generic drug competition
06/21 Put Regeneron On Your Investment Radar In 2017
Advertisement
Financials ($)
Sales 2017 23 489 M
EBIT 2017 7 190 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,78%
P/E ratio 2017 8,07
P/E ratio 2018 7,82
EV / Sales 2017 2,47x
EV / Sales 2018 2,31x
Capitalization 32 234 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-19.60%32 234
JOHNSON & JOHNSON18.42%367 520
NOVARTIS13.09%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results